ASX Announcement

Medibio Limited – 4 February 2019



Medibio Announces Extension to Entitlement Offer

Melbourne, Australia and Minneapolis, MN – 4 February 2019: Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF) advise that the Closing Date for the Non-Renounceable Entitlement Offer will be extended to 5:00pm (AEDT) 28 February 2019. The revised indicative timetable is set out below.

Closing Date of Offer	5:00 pm (AEDT), 28 February 2019
Securities quoted on a deferred settlement basis	1 March 2019
Shortfall Notification Date	5 March 2019
Shortfall Settlement date	6 March 2019
Issue date	7 March 2019
Quotation Date	12 March 2019
Despatch holding statements	13 March 2019

^{*}The above timetable is indicative only and subject to change. The quotation of Shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserve the right to vary these dates, including the Closing Date, without notice, including extending the period of the Entitlement Offer or accepting law applications, either generally or in particular cases or bringing forward the Closing Date at its discretion. Any extension of the Entitlement Offer will have a consequential effect on the issue date of the Shares.

If you wish to speak with the Company directly, please contact Melanie Leydin on +61 3 9692 7222.

Yours faithfully,

David Kaysen Managing Director and CEO

-END-

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), Perth (WA) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.